A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
NCT06349473
This study is recruiting at 7 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, or Factor VII (FVII) deficiency, with or without inhibitors (Part B).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Healthy Participants
- Hemophilia A
- Hemophilia B
- Factor VII Deficiency
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Equilibra Bioscience LLC
- Last updated on ClinicalTrials.gov
- July 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Children's Hospital Los Angeles · Los Angeles, CA
Illinois · 1
- Rush University Medical Center · Chicago, IL
Louisiana · 1
- LA Center for Bleeding and Clotting Disorders - Metairie · Metairie, LA
Michigan · 1
- University of Michigan Hospitals - Michigan Medicine · Ann Arbor, MI
Missouri · 1
- Washington University School of Medicine · St Louis, MO
Pennsylvania · 2
- Penn State Milton S Hershey Medical Center Pediatrics · Hershey, PA
- Perelman Center for Advanced Medicine (PCAM)- Penn Blood Disorders Program · Philadelphia, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.